Agenus Inc. filings document the regulatory record for a clinical-stage immuno-oncology company developing antibody-based cancer therapies, led by the BOT+BAL program of botensilimab and balstilimab. Its Form 8-K reports cover periodic financial results, clinical-program and access-program updates, material agreements, securities-related amendments and the completed disposition of manufacturing assets with related license arrangements.
Proxy and governance filings describe board matters, executive compensation, shareholder voting items and equity awards. Other event reports document officer appointments, capital-structure changes, unregistered securities activity and legal or regulatory matters affecting the company's public-company disclosures.
Agenus Inc. expanded its board of directors from six to seven members and appointed Marco Tullio Marcucci as a Class II director, effective August 5, 2026. He will serve until the 2029 annual meeting of stockholders and also join the Corporate Governance and Nominating Committee. Marcucci, age 55, is an attorney based in Rome with experience in commercial and civil law, tax and administrative litigation, wealth management, capital markets, venture capital, and cross-border transactions, including biotechnology and technology investments.
As a non-employee director, Marcucci will receive an $75,000 annual cash retainer, plus $7,500 annually for committee membership. He was granted an option to purchase 7,500 shares of common stock, vesting in three equal annual installments starting August 5, 2027, subject to continued board service. Agenus states there are no appointment arrangements, family relationships, or related-party transactions requiring disclosure.
AGENUS INC director Thomas L. Harrison received a grant of 50,000 Stock Options on August 5, 2026. The options have an exercise price of $7.78 per share, are exercisable for Common Stock, and expire on August 5, 2036. They vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in two equal annual installments thereafter. Following this award, Harrison holds 50,000 options directly.
AGENUS INC director Brian Corvese received a compensatory grant of 100,000 stock options on 2026-08-05. The options have an exercise price of $7.78 per share, expire on 2036-08-05, and were awarded under the company’s 2019 Amended and Restated Equity Incentive Plan. They vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in two equal annual installments.
Agenus Inc. reported total revenues of $68,254 (amounts in thousands) for the six months ended June 30, 2026, up from $49,757 a year earlier, driven mainly by $57,291 of non-cash royalty revenue and $10,963 of pre-commercial BOT/BAL product revenue from early access programs.
Net income attributable to common stockholders was $38,567 (thousands) versus a prior-period loss of $53,329, largely reflecting a $40,379 (thousands) gain on the Zydus asset sale and significant non-cash items, while core operations still used $67,149 (thousands) of operating cash. Cash and cash equivalents rose to $18,738 (thousands) at June 30, 2026, excluding $7,616 (thousands) in Zydus-related escrow.
After quarter end, Agenus closed an $85.0 million private placement plus up to $255.0 million of potential warrant exercise proceeds, and now expects existing cash and net placement proceeds to fund operations into the third quarter of 2027. However, management states that additional capital will be needed to complete BOT/BAL development and reach profitability, and accounting standards require disclosure that substantial doubt exists about the company’s ability to continue as a going concern.
Agenus Inc. has filed a shelf registration statement covering the potential resale by selling securityholders of up to 77,976,718 shares of common stock. This includes 1,626,015 shares already issued, 21,409,212 shares issuable upon exercise of pre-funded warrants, and 54,941,491 shares issuable upon exercise of Series A and Series B purchase warrants issued in a July 2026 private placement.
The company will not receive proceeds from any resale of shares by the selling securityholders, but will receive cash if the warrants are exercised, which it currently expects to use for general corporate and working capital purposes. Agenus had 45,009,670 shares of common stock outstanding as of July 31, 2026, and its stock last traded at $7.49 per share on August 6, 2026. The company is a clinical-stage biotechnology firm focused on immuno-oncology, with lead program botensilimab alone and in combination with balstilimab, and it recently completed an approximately $85 million private placement that created the registered securities.
Agenus Inc. reported that director Timothy Wright received a grant of 50,000 stock options under its 2019 Amended and Restated Equity Incentive Plan. The options have an exercise price of $7.78 per share, expire on August 5, 2036, and vest over three years with one-third after one year and the remainder in two equal annual installments.
AGENUS INC reported that Chief Medical Officer Steven J. O'Day received a grant of 100,000 stock options on 2026-08-05. The options have an exercise price of $7.7800 per share, expire on 2036-08-05, and were awarded under the 2019 Amended and Restated Equity Incentive Plan. They vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in two equal annual installments thereafter.
Agenus Inc. director Susan B. Hirsch received a grant of stock options covering 50,000 shares of common stock on August 5, 2026. The options have an exercise price of $7.7800 per share, expire on August 5, 2036, and were awarded under the 2019 Amended and Restated Equity Incentive Plan. They vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds in two equal annual installments.
Agenus Inc. reported that director and officer Jennifer Buell received a grant of stock options covering 200,000 shares of common stock at an exercise price of $7.78 per share. The options, expiring on August 5, 2036, were awarded under the 2019 Amended and Restated Equity Incentive Plan and vest over three years, with one-third after the first anniversary of the grant date and the remaining two-thirds in two equal annual installments. Following this grant, Buell holds 200,000 stock options directly.
Agenus Inc. reported total revenue of $34.5 million for the quarter ended June 30, 2026, compared with $25.7 million a year earlier, including $6.4 million in pre-commercial BOT+BAL product revenue and $28.1 million in non-cash royalty revenue.
The company highlighted an oversubscribed July 2026 private placement providing approximately $85 million in upfront gross proceeds plus milestone-aligned warrants that could add up to $255 million. Based on its operating plan, Agenus expects this financing to support the planned Phase 3 ROBBIN trial and company operations through the third quarter of 2027, and through year-end 2031 if all warrants are exercised.
ROBBIN will enroll about 850 patients with high-risk Stage II/III microsatellite-stable colon cancer to test neoadjuvant BOT+BAL versus surgery followed by standard care, with event-free survival as the primary endpoint. Supporting data include NEST and UNICORN neoadjuvant results in 38 patients, where about 30% achieved pathologic complete response and 40% a major pathologic response with no recurrences at data cutoffs, and a 123-patient refractory metastatic cohort showing median overall survival of 21.2 months. Agenus also expanded global access programs and discontinued funding for the CCTG-sponsored BATTMAN Phase 3 study to prioritize ROBBIN.